Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945833 | 0.93 | DGAT1 (0.45) | DGAT1PNMTHSD11B1PKMKMT2A | |
| SCHEMBL16089707 | 0.89 | TSHR (0.44) | DGAT1PNMTHSD11B1PKMKMT2A | |
| SCHEMBL25025703 | 0.82 | HSD11B1 (0.46) | DGAT1PNMTHSD11B1PKMKMT2A | |
| SCHEMBL2255789 | 0.81 | PNMT (0.42) | DGAT1PNMTKMT2AOPRM1OPRL1 | |
| SCHEMBL2450279 | 0.78 | PNMT (0.54) | PNMTAKR1C1OPRM1OPRL1HTT | |
| SCHEMBL24901900 | 0.78 | NR4A2 (0.50) | PKMKMT2ASMN1; SMN2 | |
| SCHEMBL2939567 | 0.76 | DGAT1 (0.46) | DGAT1HSD11B1KMT2ATSHRSOAT1 | |
| SCHEMBL12303003 | 0.76 | PNMT (0.38) | DGAT1PNMTKMT2AAKR1C1OPRM1 | |
| SCHEMBL16089708 | 0.74 | TSHR (0.36) | HSD11B1PKMKMT2ATSHR | |
| SCHEMBL1361875 | 0.74 | TSHR (0.58) | HSD11B1PKMKMT2ATSHRAKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-1966221-A1 | PYRIMIDO- [4, 5-]-OXAZINES FOR USE AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071966-A1 | PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| US-8017603-B2 | Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| US-7749997-B2 | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors | ASTRAZENECA AB (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966221-A1 | PYRIMIDO- [4, 5-]-OXAZINES FOR USE AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071966-A1 | PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | DGAT1 1/4885PNMT 593/4885HSD11B1 324/4885 |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | DGAT1, DGAT2, ACAT2 | DGAT1 1/4885PNMT 1950/4885HSD11B1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.